Non-Pharmacologic Management of Benign Prostatic Hyperplasia

Non-Pharmacologic Management of Benign Prostatic Hyperplasia

Non-Pharmacologic Management of Benign Prostatic Hyperplasia 150 150 Peter

Non-Pharmacologic Management of Benign Prostatic Hyperplasia

1. Provide patient educational material to assist with adherence to treatment and/or non-pharmacologic management of Benign Prostatic Hyperplasia and provide 1 reference article less than 5 years old.

2. Respond to this classmate’s post and provide 1 reference article

(Post from classmate) Benign prostatic hyperplasia (BPH) is a disease that is manifested by symptoms such as poor urinary flow, urgency, nocturia, incomplete voiding and dribbling (Ababneh et al., 2019). Typically, the treatment goal of BPH is to reduce the severity of the patient’s symptoms and prevent long-term complications. Adherence to patient medications has a significant role in reducing the severity of symptoms and improving one’s clinical outcomes. The clinician’s role in this instance is to provide adequate and thorough education to the patient regarding treatment options, their risks and benefits, and duration of treatment. It has been shown that, with verbal communication only, patients only retain about 20% of the information taught (Sare et al., 2020). Improvement of treatment adherence and clinical outcomes can occur when using both verbal and written material to ensure higher education retention rates. This written material would be better accessed through the Internet, such as a website or application, rather than brochures and pamphlets can be easily lost during traveling or in the home. One factor to be cognoscente of when creating educational material is to ensure it has high readability. On average, an American is able to read at a level of a seventh to eight grade student (Sare et al., 2020). The clinician needs to be mindful of the educational status and cognitive status of their client when providing material for treatment adherence.

Sample Paper

Advanced Pharmacology

Benign prostatic hyperplasia (BPH) is a common disorder to men as they become older. Enlarged prostate gland may cause painful urinary symptoms like blocking the urine flow from the bladder. It as well can trigger bladder, kidney or urinary tract problems. The key goals for BPH therapy are improving symptoms, arresting the disease process, and avoiding some adverse results related to BPH, like acute urinary retention and need for surgery. Adherence to BPH treatment is an essential factor in achieving ideal outcomes. Even when treatment is placebo, patients who adhere to their recommended treatment have improved health results than the poorly adherent patients. According to Neiman et al. (2017), successful approaches towards improving medication adherence may include first healthcare guaranteeing access to care providers across the care continuum and employing team-based care; secondly, care providers educating and enabling patients to understand treatment regime and its benefits; thirdly minimizing barriers to attaining medication, counting cost reduction and efforts to maintain patients in the care and finally using tools of health information technology to enhance communication and decision-making during and after the office visits.

Post to Classmate

Thank you for your contribution. I agree that Benign Prostatic Hyperplasia (BPH) is demonstrated by symptoms like poor urinary flow, nocturia, urgency and incomplete voiding and dribbling. BPH isn’t life-threatening, although it can be troublesome. Also, some complications might occur, including incapability to urinate. The goals of pharmacotherapy for BPH are reducing morbidity and preventing complications. Medications may help relax bladder neck muscles and muscle fibres in the prostate, making urination easier. These medications may include alpha-blockers, i.e., alfuzosin doxazosin, silodosin and tamsulosin (Dahm et al., 2017). These usually work fast in men with relatively small prostates. I support your point that adherence to the patient’s medications has an essential role in reducing severity of symptoms and refining clinical results. I can add that medication adherence is significant for controlling BPH, guaranteeing its overall long-term health and wellness. Nurses and physicians elaborate in patient treatment have a role in educating and enabling patients understand treatment regime and their benefits for excellent outcomes. This role can be completed through verbal and written materials to guarantee higher education retention rates. Patients should prioritize their wellness, an aspect that can be impacted by their adherence to medications as recommended by their care providers.



Dahm, P., Brasure, M., MacDonald, R., Olson, C. M., Nelson, V. A., Fink, H. A., & Wilt, T. J. (2017). Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis. European urology71(4), 570-581.

Neiman, A. B., Ruppar, T., Ho, M., Garber, L., Weidle, P. J., Hong, Y., & Thorpe, P. G. (2017). CDC grand rounds: improving medication adherence for chronic disease management—innovations and opportunities. MMWR. Morbidity and mortality weekly report66(45), 1248. Doi: 10.15585/mmwr.mm6645a2